| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyCellularComponent | paraspeckles | 7.40e-06 | 10 | 9 | 2 | GO:0042382 | |
| GeneOntologyCellularComponent | neuron projection cytoplasm | 9.64e-04 | 110 | 9 | 2 | GO:0120111 | |
| GeneOntologyCellularComponent | nuclear matrix | 1.55e-03 | 140 | 9 | 2 | GO:0016363 | |
| GeneOntologyCellularComponent | transcription regulator complex | 1.70e-03 | 596 | 9 | 3 | GO:0005667 | |
| GeneOntologyCellularComponent | fibrillar center | 1.92e-03 | 156 | 9 | 2 | GO:0001650 | |
| GeneOntologyCellularComponent | nuclear periphery | 2.31e-03 | 171 | 9 | 2 | GO:0034399 | |
| GeneOntologyCellularComponent | nuclear body | 5.55e-03 | 903 | 9 | 3 | GO:0016604 | |
| GeneOntologyCellularComponent | RNA polymerase II transcription regulator complex | 5.72e-03 | 272 | 9 | 2 | GO:0090575 | |
| GeneOntologyCellularComponent | plasma membrane bounded cell projection cytoplasm | 7.69e-03 | 317 | 9 | 2 | GO:0032838 | |
| MousePheno | abnormal rhythmic behavior | 1.03e-04 | 204 | 7 | 3 | MP:0021121 | |
| Domain | NOPS | 6.19e-07 | 3 | 9 | 2 | PF08075 | |
| Domain | NOPS | 6.19e-07 | 3 | 9 | 2 | IPR012975 | |
| Domain | RRM_1 | 4.22e-03 | 208 | 9 | 2 | PF00076 | |
| Domain | RRM | 4.58e-03 | 217 | 9 | 2 | SM00360 | |
| Domain | RRM_dom | 5.00e-03 | 227 | 9 | 2 | IPR000504 | |
| Domain | RRM | 5.13e-03 | 230 | 9 | 2 | PS50102 | |
| Domain | - | 5.76e-03 | 244 | 9 | 2 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 6.42e-03 | 258 | 9 | 2 | IPR012677 | |
| Pubmed | 5.95e-08 | 2 | 9 | 2 | 25765647 | ||
| Pubmed | 5.95e-08 | 2 | 9 | 2 | 12417296 | ||
| Pubmed | Purification and characterization of a DNA-binding heterodimer of 52 and 100 kDa from HeLa cells. | 5.95e-08 | 2 | 9 | 2 | 8439294 | |
| Pubmed | Molecular Modelling of NONO and SFPQ Dimerization Process and RNA Recognition Mechanism. | 5.95e-08 | 2 | 9 | 2 | 35886974 | |
| Pubmed | 5.95e-08 | 2 | 9 | 2 | 25605962 | ||
| Pubmed | The PSF.p54nrb complex is a novel Mnk substrate that binds the mRNA for tumor necrosis factor alpha. | 5.95e-08 | 2 | 9 | 2 | 17965020 | |
| Pubmed | 5.95e-08 | 2 | 9 | 2 | 27924002 | ||
| Pubmed | PSF/p54(nrb) stimulates "jumping" of DNA topoisomerase I between separate DNA helices. | 5.95e-08 | 2 | 9 | 2 | 10858305 | |
| Pubmed | 5.95e-08 | 2 | 9 | 2 | 12944487 | ||
| Pubmed | 5.95e-08 | 2 | 9 | 2 | 15590677 | ||
| Pubmed | 1.69e-07 | 45 | 9 | 3 | 33596420 | ||
| Pubmed | hnRNP M interacts with PSF and p54(nrb) and co-localizes within defined nuclear structures. | 1.79e-07 | 3 | 9 | 2 | 19874820 | |
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 30445466 | ||
| Pubmed | Proteomic identification of a PSF/p54nrb heterodimer as RNF43 oncoprotein-interacting proteins. | 1.79e-07 | 3 | 9 | 2 | 18655028 | |
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 25326457 | ||
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 16641145 | ||
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 17639083 | ||
| Pubmed | Proteomic identification of PSF and p54(nrb) as TopBP1-interacting proteins. | 1.79e-07 | 3 | 9 | 2 | 22213094 | |
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 15790595 | ||
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 11525732 | ||
| Pubmed | Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response. | 1.79e-07 | 3 | 9 | 2 | 20421735 | |
| Pubmed | P54nrb forms a heterodimer with PSP1 that localizes to paraspeckles in an RNA-dependent manner. | 1.79e-07 | 3 | 9 | 2 | 16148043 | |
| Pubmed | 1.79e-07 | 3 | 9 | 2 | 9393982 | ||
| Pubmed | 3.57e-07 | 4 | 9 | 2 | 32764370 | ||
| Pubmed | 3.57e-07 | 4 | 9 | 2 | 27259250 | ||
| Pubmed | The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I activity by a direct interaction. | 3.57e-07 | 4 | 9 | 2 | 9756848 | |
| Pubmed | 5.95e-07 | 5 | 9 | 2 | 17452459 | ||
| Pubmed | 5.95e-07 | 5 | 9 | 2 | 11897684 | ||
| Pubmed | 5.95e-07 | 5 | 9 | 2 | 17507659 | ||
| Pubmed | Dynamic paraspeckle component localisation during spermatogenesis. | 5.95e-07 | 5 | 9 | 2 | 31299635 | |
| Pubmed | Distinct roles of DBHS family members in the circadian transcriptional feedback loop. | 5.95e-07 | 5 | 9 | 2 | 22966205 | |
| Pubmed | 5.95e-07 | 5 | 9 | 2 | 28846091 | ||
| Pubmed | The mitotic phosphorylation of p54(nrb) modulates its RNA binding activity. | 5.95e-07 | 5 | 9 | 2 | 21819346 | |
| Pubmed | 8.92e-07 | 6 | 9 | 2 | 11259580 | ||
| Pubmed | 8.92e-07 | 6 | 9 | 2 | 19389484 | ||
| Pubmed | 8.92e-07 | 6 | 9 | 2 | 30423030 | ||
| Pubmed | Malat1 is not an essential component of nuclear speckles in mice. | 1.25e-06 | 7 | 9 | 2 | 22718948 | |
| Pubmed | 1.25e-06 | 7 | 9 | 2 | 12403470 | ||
| Pubmed | 1.67e-06 | 8 | 9 | 2 | 18042045 | ||
| Pubmed | 2.14e-06 | 9 | 9 | 2 | 21566083 | ||
| Pubmed | Transcription factor protein interactomes reveal genetic determinants in heart disease. | 2.31e-06 | 411 | 9 | 4 | 35182466 | |
| Pubmed | 2.68e-06 | 10 | 9 | 2 | 28712728 | ||
| Pubmed | 3.27e-06 | 11 | 9 | 2 | 15215307 | ||
| Pubmed | 4.64e-06 | 13 | 9 | 2 | 30725116 | ||
| Pubmed | A molecular mechanism for circadian clock negative feedback. | 4.64e-06 | 13 | 9 | 2 | 21680841 | |
| Pubmed | 4.64e-06 | 13 | 9 | 2 | 19144721 | ||
| Pubmed | HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. | 6.23e-06 | 148 | 9 | 3 | 32538781 | |
| Pubmed | 6.24e-06 | 15 | 9 | 2 | 16417406 | ||
| Pubmed | 1.02e-05 | 19 | 9 | 2 | 34467244 | ||
| Pubmed | TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. | 1.37e-05 | 22 | 9 | 2 | 17803295 | |
| Pubmed | 1.50e-05 | 23 | 9 | 2 | 21670149 | ||
| Pubmed | Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition. | 2.24e-05 | 28 | 9 | 2 | 19596686 | |
| Pubmed | 2.41e-05 | 29 | 9 | 2 | 19279220 | ||
| Pubmed | 2.41e-05 | 29 | 9 | 2 | 34175335 | ||
| Pubmed | Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors. | 2.58e-05 | 30 | 9 | 2 | 34017080 | |
| Pubmed | Proteomic analysis of complexes formed by human topoisomerase I. | 2.94e-05 | 32 | 9 | 2 | 15848144 | |
| Pubmed | 2.94e-05 | 32 | 9 | 2 | 19542561 | ||
| Pubmed | 2.94e-05 | 32 | 9 | 2 | 36252997 | ||
| Pubmed | 2.94e-05 | 32 | 9 | 2 | 31815296 | ||
| Pubmed | 3.34e-05 | 809 | 9 | 4 | 32129710 | ||
| Pubmed | Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells. | 4.32e-05 | 283 | 9 | 3 | 30585729 | |
| Pubmed | 5.14e-05 | 300 | 9 | 3 | 28561026 | ||
| Pubmed | 5.35e-05 | 43 | 9 | 2 | 26030138 | ||
| Pubmed | Functional specialization of beta-arrestin interactions revealed by proteomic analysis. | 6.05e-05 | 317 | 9 | 3 | 17620599 | |
| Pubmed | 6.12e-05 | 46 | 9 | 2 | 19928837 | ||
| Pubmed | 6.67e-05 | 48 | 9 | 2 | 24302573 | ||
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | 7.31e-05 | 989 | 9 | 4 | 36424410 | |
| Pubmed | Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. | 7.84e-05 | 52 | 9 | 2 | 24591637 | |
| Pubmed | 8.15e-05 | 53 | 9 | 2 | 36841324 | ||
| Pubmed | 8.46e-05 | 54 | 9 | 2 | 18495661 | ||
| Pubmed | CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110). | 8.78e-05 | 55 | 9 | 2 | 23178491 | |
| Pubmed | 9.43e-05 | 57 | 9 | 2 | 38223760 | ||
| Pubmed | Human GW182 Paralogs Are the Central Organizers for RNA-Mediated Control of Transcription. | 1.01e-04 | 59 | 9 | 2 | 28813667 | |
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | 1.04e-04 | 1082 | 9 | 4 | 38697112 | |
| Pubmed | 1.15e-04 | 63 | 9 | 2 | 37052853 | ||
| Pubmed | 1.27e-04 | 66 | 9 | 2 | 23472066 | ||
| Pubmed | The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically. | 1.27e-04 | 66 | 9 | 2 | 32051553 | |
| Pubmed | SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein. | 1.27e-04 | 66 | 9 | 2 | 36095012 | |
| Pubmed | 1.64e-04 | 75 | 9 | 2 | 31527668 | ||
| Pubmed | Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation. | 1.79e-04 | 457 | 9 | 3 | 32344865 | |
| Pubmed | 1.79e-04 | 1247 | 9 | 4 | 27684187 | ||
| Pubmed | Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. | 2.05e-04 | 84 | 9 | 2 | 19135240 | |
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | 2.07e-04 | 1294 | 9 | 4 | 30804502 | |
| Pubmed | 2.14e-04 | 486 | 9 | 3 | 20936779 | ||
| Pubmed | 14-3-3sigma controls mitotic translation to facilitate cytokinesis. | 2.15e-04 | 86 | 9 | 2 | 17361185 | |
| Pubmed | 2.20e-04 | 87 | 9 | 2 | 33711283 | ||
| Pubmed | Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. | 2.26e-04 | 495 | 9 | 3 | 28581483 | |
| Pubmed | DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation. | 2.30e-04 | 89 | 9 | 2 | 22446626 | |
| Pubmed | Proteomics analysis of the estrogen receptor alpha receptosome. | 2.52e-04 | 93 | 9 | 2 | 20348541 | |
| Pubmed | 2.58e-04 | 1371 | 9 | 4 | 36244648 | ||
| Interaction | APBB1 interactions | 1.03e-06 | 195 | 9 | 4 | int:APBB1 | |
| Interaction | PITX3 interactions | 4.96e-06 | 8 | 9 | 2 | int:PITX3 | |
| Interaction | KIF23 interactions | 3.68e-05 | 1031 | 9 | 5 | int:KIF23 | |
| Interaction | NEAT1 interactions | 4.87e-05 | 24 | 9 | 2 | int:NEAT1 | |
| Interaction | LMO7 interactions | 5.38e-05 | 177 | 9 | 3 | int:LMO7 | |
| Interaction | PPP1R10 interactions | 5.56e-05 | 179 | 9 | 3 | int:PPP1R10 | |
| Interaction | NKX2-1 interactions | 5.66e-05 | 180 | 9 | 3 | int:NKX2-1 | |
| Interaction | ASB18 interactions | 6.19e-05 | 27 | 9 | 2 | int:ASB18 | |
| Interaction | SLX4 interactions | 7.22e-05 | 572 | 9 | 4 | int:SLX4 | |
| Interaction | TCERG1 interactions | 8.57e-05 | 207 | 9 | 3 | int:TCERG1 | |
| Interaction | UBE2M interactions | 1.19e-04 | 651 | 9 | 4 | int:UBE2M | |
| Interaction | LINC00624 interactions | 1.30e-04 | 39 | 9 | 2 | int:LINC00624 | |
| Interaction | CDK9 interactions | 1.45e-04 | 685 | 9 | 4 | int:CDK9 | |
| Interaction | BFAR interactions | 1.98e-04 | 48 | 9 | 2 | int:BFAR | |
| Interaction | TSPYL5 interactions | 2.23e-04 | 51 | 9 | 2 | int:TSPYL5 | |
| Interaction | SMN1 interactions | 2.54e-04 | 299 | 9 | 3 | int:SMN1 | |
| Interaction | KMT2A interactions | 2.94e-04 | 314 | 9 | 3 | int:KMT2A | |
| Interaction | IGFBP3 interactions | 3.20e-04 | 61 | 9 | 2 | int:IGFBP3 | |
| Interaction | RUNX1 interactions | 3.22e-04 | 324 | 9 | 3 | int:RUNX1 | |
| Interaction | ELP4 interactions | 3.31e-04 | 62 | 9 | 2 | int:ELP4 | |
| Interaction | CDC5L interactions | 3.42e-04 | 855 | 9 | 4 | int:CDC5L | |
| Interaction | MIR138-1 interactions | 3.98e-04 | 68 | 9 | 2 | int:MIR138-1 | |
| Interaction | MIR9-3 interactions | 4.21e-04 | 70 | 9 | 2 | int:MIR9-3 | |
| Interaction | KAT5 interactions | 4.31e-04 | 358 | 9 | 3 | int:KAT5 | |
| Interaction | MIR29B2 interactions | 4.34e-04 | 71 | 9 | 2 | int:MIR29B2 | |
| Interaction | MIR140 interactions | 4.34e-04 | 71 | 9 | 2 | int:MIR140 | |
| Interaction | MIR122 interactions | 4.34e-04 | 71 | 9 | 2 | int:MIR122 | |
| Interaction | MIR29B1 interactions | 4.58e-04 | 73 | 9 | 2 | int:MIR29B1 | |
| Interaction | MIR18A interactions | 4.58e-04 | 73 | 9 | 2 | int:MIR18A | |
| Interaction | MIR20A interactions | 4.71e-04 | 74 | 9 | 2 | int:MIR20A | |
| Interaction | CSF1R interactions | 4.84e-04 | 75 | 9 | 2 | int:CSF1R | |
| Interaction | MIR15A interactions | 4.84e-04 | 75 | 9 | 2 | int:MIR15A | |
| Interaction | MIR429 interactions | 4.97e-04 | 76 | 9 | 2 | int:MIR429 | |
| Interaction | MIR16-1 interactions | 4.97e-04 | 76 | 9 | 2 | int:MIR16-1 | |
| Interaction | MIR7-3 interactions | 4.97e-04 | 76 | 9 | 2 | int:MIR7-3 | |
| Interaction | MIR199A2 interactions | 4.97e-04 | 76 | 9 | 2 | int:MIR199A2 | |
| Interaction | MIR9-2 interactions | 5.10e-04 | 77 | 9 | 2 | int:MIR9-2 | |
| Interaction | MIR200A interactions | 5.10e-04 | 77 | 9 | 2 | int:MIR200A | |
| Interaction | SIN3A interactions | 5.13e-04 | 380 | 9 | 3 | int:SIN3A | |
| Interaction | MIR451A interactions | 5.23e-04 | 78 | 9 | 2 | int:MIR451A | |
| Interaction | MIR98 interactions | 5.23e-04 | 78 | 9 | 2 | int:MIR98 | |
| Interaction | MIR92A1 interactions | 5.23e-04 | 78 | 9 | 2 | int:MIR92A1 | |
| Interaction | PIN1 interactions | 5.25e-04 | 383 | 9 | 3 | int:PIN1 | |
| Interaction | SMARCC1 interactions | 5.29e-04 | 384 | 9 | 3 | int:SMARCC1 | |
| Interaction | MIR222 interactions | 5.37e-04 | 79 | 9 | 2 | int:MIR222 | |
| Interaction | MIR206 interactions | 5.37e-04 | 79 | 9 | 2 | int:MIR206 | |
| Interaction | MIR34C interactions | 5.37e-04 | 79 | 9 | 2 | int:MIR34C | |
| Interaction | MIR1-2 interactions | 5.37e-04 | 79 | 9 | 2 | int:MIR1-2 | |
| Interaction | MIR143 interactions | 5.50e-04 | 80 | 9 | 2 | int:MIR143 | |
| Interaction | MIR145 interactions | 5.64e-04 | 81 | 9 | 2 | int:MIR145 | |
| Interaction | MIR10B interactions | 5.78e-04 | 82 | 9 | 2 | int:MIR10B | |
| Interaction | MIR106A interactions | 5.92e-04 | 83 | 9 | 2 | int:MIR106A | |
| Interaction | AR interactions | 6.03e-04 | 992 | 9 | 4 | int:AR | |
| Interaction | NR2C1 interactions | 6.06e-04 | 84 | 9 | 2 | int:NR2C1 | |
| Interaction | ASB3 interactions | 6.06e-04 | 84 | 9 | 2 | int:ASB3 | |
| Interaction | MIR200B interactions | 6.06e-04 | 84 | 9 | 2 | int:MIR200B | |
| Interaction | MIR7-2 interactions | 6.06e-04 | 84 | 9 | 2 | int:MIR7-2 | |
| Interaction | MIR31 interactions | 6.06e-04 | 84 | 9 | 2 | int:MIR31 | |
| Interaction | MIR199A1 interactions | 6.06e-04 | 84 | 9 | 2 | int:MIR199A1 | |
| Interaction | MIR16-2 interactions | 6.21e-04 | 85 | 9 | 2 | int:MIR16-2 | |
| Interaction | MIR93 interactions | 6.21e-04 | 85 | 9 | 2 | int:MIR93 | |
| Interaction | MIR9-1 interactions | 6.21e-04 | 85 | 9 | 2 | int:MIR9-1 | |
| Interaction | MIR107 interactions | 6.21e-04 | 85 | 9 | 2 | int:MIR107 | |
| Interaction | MIR17 interactions | 6.21e-04 | 85 | 9 | 2 | int:MIR17 | |
| Interaction | MIR18B interactions | 6.21e-04 | 85 | 9 | 2 | int:MIR18B | |
| Interaction | MIR20B interactions | 6.35e-04 | 86 | 9 | 2 | int:MIR20B | |
| Interaction | GATA4 interactions | 6.46e-04 | 411 | 9 | 3 | int:GATA4 | |
| Interaction | MIR29A interactions | 6.50e-04 | 87 | 9 | 2 | int:MIR29A | |
| Interaction | MIR141 interactions | 6.65e-04 | 88 | 9 | 2 | int:MIR141 | |
| Interaction | MIR138-2 interactions | 6.65e-04 | 88 | 9 | 2 | int:MIR138-2 | |
| Interaction | MIR29C interactions | 6.80e-04 | 89 | 9 | 2 | int:MIR29C | |
| Interaction | MEN1 interactions | 6.92e-04 | 1029 | 9 | 4 | int:MEN1 | |
| Interaction | MIR221 interactions | 6.96e-04 | 90 | 9 | 2 | int:MIR221 | |
| Interaction | MIR92A2 interactions | 6.96e-04 | 90 | 9 | 2 | int:MIR92A2 | |
| Interaction | MIR1-1 interactions | 6.96e-04 | 90 | 9 | 2 | int:MIR1-1 | |
| Interaction | NUP35 interactions | 7.07e-04 | 424 | 9 | 3 | int:NUP35 | |
| Interaction | MIR200C interactions | 7.11e-04 | 91 | 9 | 2 | int:MIR200C | |
| Interaction | MIR128-1 interactions | 7.27e-04 | 92 | 9 | 2 | int:MIR128-1 | |
| Interaction | MIR155 interactions | 7.27e-04 | 92 | 9 | 2 | int:MIR155 | |
| Interaction | MIR214 interactions | 7.43e-04 | 93 | 9 | 2 | int:MIR214 | |
| Interaction | MIR205 interactions | 7.43e-04 | 93 | 9 | 2 | int:MIR205 | |
| Interaction | MIR19B2 interactions | 7.59e-04 | 94 | 9 | 2 | int:MIR19B2 | |
| Interaction | MIRLET7F1 interactions | 7.59e-04 | 94 | 9 | 2 | int:MIRLET7F1 | |
| Interaction | TOPORS interactions | 7.91e-04 | 96 | 9 | 2 | int:TOPORS | |
| Interaction | MIRLET7A2 interactions | 7.91e-04 | 96 | 9 | 2 | int:MIRLET7A2 | |
| Interaction | MIRLET7C interactions | 8.07e-04 | 97 | 9 | 2 | int:MIRLET7C | |
| Interaction | MIR21 interactions | 8.07e-04 | 97 | 9 | 2 | int:MIR21 | |
| Interaction | MIRLET7F2 interactions | 8.07e-04 | 97 | 9 | 2 | int:MIRLET7F2 | |
| Interaction | MIR363 interactions | 8.07e-04 | 97 | 9 | 2 | int:MIR363 | |
| Interaction | PRPF40A interactions | 8.19e-04 | 446 | 9 | 3 | int:PRPF40A | |
| Interaction | MIR106B interactions | 8.24e-04 | 98 | 9 | 2 | int:MIR106B | |
| Interaction | FAM76B interactions | 8.41e-04 | 99 | 9 | 2 | int:FAM76B | |
| Interaction | MIR128-2 interactions | 8.41e-04 | 99 | 9 | 2 | int:MIR128-2 | |
| Interaction | NDN interactions | 8.57e-04 | 453 | 9 | 3 | int:NDN | |
| Interaction | PER1 interactions | 8.58e-04 | 100 | 9 | 2 | int:PER1 | |
| Interaction | MIR19A interactions | 8.58e-04 | 100 | 9 | 2 | int:MIR19A | |
| Interaction | ARRB2 interactions | 8.62e-04 | 454 | 9 | 3 | int:ARRB2 | |
| Interaction | MIRLET7B interactions | 8.75e-04 | 101 | 9 | 2 | int:MIRLET7B | |
| Interaction | MIRLET7D interactions | 8.75e-04 | 101 | 9 | 2 | int:MIRLET7D | |
| Interaction | MIR25 interactions | 8.75e-04 | 101 | 9 | 2 | int:MIR25 | |
| GeneFamily | Armadillo repeat containing|Protein phosphatase 1 regulatory subunits | 5.90e-04 | 181 | 4 | 2 | 694 | |
| GeneFamily | RNA binding motif containing | 8.16e-04 | 213 | 4 | 2 | 725 | |
| Coexpression | CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN | 1.15e-05 | 465 | 9 | 4 | M9192 | |
| Coexpression | GSE20198_UNTREATED_VS_IL12_IL18_TREATED_ACT_CD4_TCELL_UP | 3.50e-05 | 199 | 9 | 3 | M7379 | |
| Coexpression | CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN | 1.38e-04 | 52 | 9 | 2 | M12895 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE | 2.08e-04 | 363 | 9 | 3 | M41103 | |
| Coexpression | YOSHIMURA_MAPK8_TARGETS_DN | 2.36e-04 | 379 | 9 | 3 | M1885 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN | 3.47e-04 | 432 | 9 | 3 | M41149 | |
| Coexpression | ROPERO_HDAC2_TARGETS | 6.39e-04 | 112 | 9 | 2 | M8759 | |
| Coexpression | KIM_ALL_DISORDERS_CALB1_CORR_UP | 6.91e-04 | 547 | 9 | 3 | M2110 | |
| Coexpression | FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN | 7.14e-04 | 553 | 9 | 3 | M1475 | |
| Coexpression | CERVERA_SDHB_TARGETS_1_UP | 7.33e-04 | 120 | 9 | 2 | M15549 | |
| Coexpression | FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP | 7.71e-04 | 568 | 9 | 3 | M4023 | |
| Coexpression | LAKE_ADULT_KIDNEY_C24_ENDOTHELIAL_CELLS_AEA_AND_DVR | 1.17e-03 | 152 | 9 | 2 | M39243 | |
| Coexpression | CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN | 1.24e-03 | 669 | 9 | 3 | M18635 | |
| Coexpression | KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_UP | 1.30e-03 | 680 | 9 | 3 | M2107 | |
| Coexpression | GSE37532_TREG_VS_TCONV_CD4_TCELL_FROM_VISCERAL_ADIPOSE_TISSUE_DN | 1.44e-03 | 169 | 9 | 2 | M8937 | |
| Coexpression | XIE_TRASTUZUMAB_CARDIOTOXICITY_MMU_MIR_669C_3P_GENES | 1.69e-03 | 183 | 9 | 2 | MM17506 | |
| Coexpression | JISON_SICKLE_CELL_DISEASE_DN | 1.75e-03 | 186 | 9 | 2 | M4911 | |
| Coexpression | GSE17974_0.5H_VS_72H_UNTREATED_IN_VITRO_CD4_TCELL_UP | 1.90e-03 | 194 | 9 | 2 | M4234 | |
| Coexpression | GSE36476_YOUNG_VS_OLD_DONOR_MEMORY_CD4_TCELL_40H_TSST_ACT_UP | 1.92e-03 | 195 | 9 | 2 | M5318 | |
| Coexpression | GSE11864_UNTREATED_VS_CSF1_IFNG_PAM3CYS_IN_MAC_UP | 1.97e-03 | 198 | 9 | 2 | M3131 | |
| Coexpression | GSE16386_IL4_VS_IL4_AND_ROSIGLITAZONE_STIM_MACROPHAGE_6H_DN | 1.97e-03 | 198 | 9 | 2 | M7916 | |
| Coexpression | GSE20500_RETINOIC_ACID_VS_RARA_ANTAGONIST_TREATED_CD4_TCELL_DN | 1.97e-03 | 198 | 9 | 2 | M7708 | |
| Coexpression | GSE45365_NK_CELL_VS_BCELL_UP | 1.97e-03 | 198 | 9 | 2 | M10031 | |
| Coexpression | HALLMARK_MITOTIC_SPINDLE | 1.99e-03 | 199 | 9 | 2 | M5893 | |
| Coexpression | GSE22886_NEUTROPHIL_VS_MONOCYTE_DN | 1.99e-03 | 199 | 9 | 2 | M4467 | |
| Coexpression | GSE21033_CTRL_VS_POLYIC_STIM_DC_6H_UP | 1.99e-03 | 199 | 9 | 2 | M7712 | |
| Coexpression | GSE15930_STIM_VS_STIM_AND_TRICHOSTATINA_24H_CD8_T_CELL_UP | 1.99e-03 | 199 | 9 | 2 | M3627 | |
| Coexpression | GSE17721_PAM3CSK4_VS_CPG_1H_BMDC_DN | 1.99e-03 | 199 | 9 | 2 | M3853 | |
| Coexpression | GSE19888_CTRL_VS_A3R_ACT_TREATED_MAST_CELL_PRETREATED_WITH_A3R_INH_DN | 1.99e-03 | 199 | 9 | 2 | M7351 | |
| Coexpression | ONKEN_UVEAL_MELANOMA_UP | 2.00e-03 | 790 | 9 | 3 | M12490 | |
| Coexpression | GSE17721_LPS_VS_CPG_2H_BMDC_DN | 2.01e-03 | 200 | 9 | 2 | M3991 | |
| Coexpression | GSE14769_20MIN_VS_360MIN_LPS_BMDM_DN | 2.01e-03 | 200 | 9 | 2 | M3513 | |
| Coexpression | GSE36392_MAC_VS_NEUTROPHIL_IL25_TREATED_LUNG_DN | 2.01e-03 | 200 | 9 | 2 | M5286 | |
| Coexpression | GSE27859_DC_VS_CD11C_INT_F480_INT_DC_UP | 2.01e-03 | 200 | 9 | 2 | M8596 | |
| Coexpression | GSE3337_CTRL_VS_4H_IFNG_IN_CD8POS_DC_DN | 2.01e-03 | 200 | 9 | 2 | M5099 | |
| Coexpression | GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_DN | 2.01e-03 | 200 | 9 | 2 | M5582 | |
| Coexpression | GSE339_CD4POS_VS_CD4CD8DN_DC_IN_CULTURE_UP | 2.01e-03 | 200 | 9 | 2 | M5122 | |
| Coexpression | GSE5589_LPS_VS_LPS_AND_IL6_STIM_MACROPHAGE_45MIN_UP | 2.01e-03 | 200 | 9 | 2 | M6611 | |
| Coexpression | GSE9006_HEALTHY_VS_TYPE_2_DIABETES_PBMC_AT_DX_UP | 2.01e-03 | 200 | 9 | 2 | M5781 | |
| Coexpression | GSE11961_MEMORY_BCELL_DAY7_VS_PLASMA_CELL_DAY7_DN | 2.01e-03 | 200 | 9 | 2 | M9368 | |
| Coexpression | GSE557_WT_VS_I_AB_KO_DC_DN | 2.01e-03 | 200 | 9 | 2 | M6010 | |
| Coexpression | GSE3982_MAC_VS_BCELL_UP | 2.01e-03 | 200 | 9 | 2 | M5494 | |
| Coexpression | GSE7831_UNSTIM_VS_INFLUENZA_STIM_PDC_4H_DN | 2.01e-03 | 200 | 9 | 2 | M6956 | |
| Coexpression | BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP | 2.24e-03 | 822 | 9 | 3 | M6782 | |
| Coexpression | BIDUS_METASTASIS_UP | 2.45e-03 | 221 | 9 | 2 | M15866 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#3_top-relative-expression-ranked_200 | 2.16e-05 | 17 | 9 | 2 | gudmap_developingGonad_e16.5_epididymis_200_k3 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#3_top-relative-expression-ranked_200 | 4.77e-05 | 25 | 9 | 2 | gudmap_developingGonad_e14.5_ epididymis_200_k3 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#5_top-relative-expression-ranked_500 | 1.24e-04 | 40 | 9 | 2 | gudmap_developingGonad_e16.5_epididymis_500_k5 | |
| CoexpressionAtlas | DevelopingKidney_e15.5_Medullary collecting duct_emap-28063_k-means-cluster#4_top-relative-expression-ranked_1000 | 1.46e-04 | 261 | 9 | 3 | gudmap_developingKidney_e15.5_Medullary collecting duct_1000_k4 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#1_top-relative-expression-ranked_500 | 1.94e-04 | 50 | 9 | 2 | gudmap_developingGonad_e14.5_ epididymis_500_k1 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#1_top-relative-expression-ranked_1000 | 7.58e-04 | 99 | 9 | 2 | gudmap_developingGonad_e14.5_ epididymis_1000_k1 | |
| ToppCell | Bronchial-10x5prime-Endothelial-Endothelia_vascular-VE_systemic_arterial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 7.02e-06 | 199 | 9 | 3 | 6a2943a23fdd2ec814662db7c21a0d6804a6cbbc | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2-Sox4-POLYDENDROCYTE_(Neurogenesis.Sox4.Gad2)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 2.68e-04 | 124 | 9 | 2 | 1483be8700eca7e2c288784a290d945d4022b17f | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.22e-04 | 136 | 9 | 2 | 3e13dc0634f3b05e9f9e6c3193f843f62e603b78 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2-Sox4|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.22e-04 | 136 | 9 | 2 | 0185486c39700dd2f72d79be6d283494dd8379c9 | |
| ToppCell | droplet-Liver-Hepatocytes-24m-Lymphocytic-NK/T|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.29e-04 | 157 | 9 | 2 | 16581e2399a211633f870dce326c75ff4b6a5fe6 | |
| ToppCell | droplet-Liver-Hepatocytes-24m-Lymphocytic-NK_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.29e-04 | 157 | 9 | 2 | cbb08d5c151f0622123276926a2a15bb7d271e90 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell_prolif|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.62e-04 | 163 | 9 | 2 | 1feb4ef7b8abcfca9a72c8d13c40548de79e7db2 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.20e-04 | 173 | 9 | 2 | 85083b9ce20351dd69aa2327ad087b848b4307ff | |
| ToppCell | ASK452-Endothelial-Lymphatic|ASK452 / Donor, Lineage and Cell class of Lung cells from Dropseq | 5.38e-04 | 176 | 9 | 2 | b4d280ecc07701d526f50d44c45ea91b3eeb00b1 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 5.63e-04 | 180 | 9 | 2 | 44988c34861df359a68376500c42a64fbcc4b431 | |
| ToppCell | 10x3'2.3-week_12-13-Mesenchymal_osteo-stroma-chondrocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.75e-04 | 182 | 9 | 2 | ed487f3a774812caa2903a646b60c86edcc1e65e | |
| ToppCell | Striatum-Macroglia-POLYDENDROCYTE-P5|Striatum / BrainAtlas - Mouse McCarroll V32 | 5.81e-04 | 183 | 9 | 2 | f20b0d71f857ac35868fd80531050ad8b6091716 | |
| ToppCell | facs-Limb_Muscle-ForelimbandHindlimb|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.94e-04 | 185 | 9 | 2 | eb7d3c1363d5fedc611f9c1a91ea823de251355e | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 6.13e-04 | 188 | 9 | 2 | 8bd6f2cd1aadbd6f9ed31b160f59c1eff144e1dc | |
| ToppCell | PND10|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.26e-04 | 190 | 9 | 2 | d67e2814047c8df2ae4b7bc8be9539f5df6ecef2 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Alv_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.26e-04 | 190 | 9 | 2 | 474cbbab8f3b0a6881fa6c92edb78e43999f9ab0 | |
| ToppCell | Striatum-Macroglia-POLYDENDROCYTE|Striatum / BrainAtlas - Mouse McCarroll V32 | 6.33e-04 | 191 | 9 | 2 | 6bc9c7c86040f3ebce08c350e625e345581d4550 | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular-Endothelial_large_blood_vessel-AEC|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.33e-04 | 191 | 9 | 2 | 50601ef0a5a8f2c2120922989e08e85bf2d9b4ab | |
| ToppCell | 5'-Adult-SmallIntestine-Endothelial-lymphatic_endothelial-LEC3_(ADGRG3+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.46e-04 | 193 | 9 | 2 | bd0027fa97de41ae22ff64a61c8e217496f122ca | |
| ToppCell | COPD-Endothelial-VE_Arterial|COPD / Disease state, Lineage and Cell class | 6.46e-04 | 193 | 9 | 2 | 1c701b6ab5f0f0239634adac94fa1c92bf3c36f4 | |
| ToppCell | CV-Moderate-6|Moderate / Virus stimulation, Condition and Cluster | 6.59e-04 | 195 | 9 | 2 | 2b8a72d7e755b9655c7a496000d10ff06e50862b | |
| ToppCell | proximal-Hematologic-IGSF21+_Dendritic-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.59e-04 | 195 | 9 | 2 | ae9d61011e95f7840cbb154738c79745fd29943e | |
| ToppCell | proximal-Hematologic-IGSF21+_Dendritic|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.59e-04 | 195 | 9 | 2 | c48ff83c48342875f06c6c9e7d5bc6084a992848 | |
| ToppCell | proximal-3-Hematologic-IGSF21+_Dendritic|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.59e-04 | 195 | 9 | 2 | 8592d0332bc82a91e173680cfd1afc5ee189b289 | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular-Endothelial_large_blood_vessel|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.59e-04 | 195 | 9 | 2 | 023e3c97dd3696d74f002ff8da0c04d876c82aef | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.59e-04 | 195 | 9 | 2 | b0979c1b5e4576468b8fe4e9027650859e598b34 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.59e-04 | 195 | 9 | 2 | 3e519cffa6144a62b06124642a14c9ff39b76554 | |
| ToppCell | CV-Moderate-6|CV / Virus stimulation, Condition and Cluster | 6.66e-04 | 196 | 9 | 2 | 7bced0cc2112697593c478fa291b8ed3941fb811 | |
| ToppCell | facs-Limb_Muscle-ForelimbandHindlimb-3m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.66e-04 | 196 | 9 | 2 | 151f1a29a91f8b234e9b6ed062666357a2f69128 | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.66e-04 | 196 | 9 | 2 | 686533fd3fba8e4df96b9dd1307e870e89db4332 | |
| ToppCell | nucseq-Endothelial|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.73e-04 | 197 | 9 | 2 | ebf9be068eaa658493fa7884fd19f34642922acb | |
| ToppCell | facs-Trachea-3m|Trachea / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.73e-04 | 197 | 9 | 2 | e77016d64b1cac9825fec7cfe5071f1567401187 | |
| ToppCell | facs-Brain_Non-Myeloid|facs / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.73e-04 | 197 | 9 | 2 | a1f7eec1aca03432caa8fe817ff6d24b29d4062d | |
| ToppCell | facs-Trachea-nan-3m|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.73e-04 | 197 | 9 | 2 | 0353d925ee4b7aefc2c51b5fab873f465cdf9ebc | |
| ToppCell | facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l1|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.73e-04 | 197 | 9 | 2 | 3fe665c0277d091290b63f0dd24c0c6536a45309 | |
| ToppCell | 5'-Adult-SmallIntestine-Endothelial-lymphatic_endothelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.73e-04 | 197 | 9 | 2 | 407231542fa1ffd540dcb61435c0575e71f59725 | |
| ToppCell | facs-Tongue-nan-3m-Epithelial|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.80e-04 | 198 | 9 | 2 | 2f03f8897dd7cce6d8296638e14e11ec16bcf624 | |
| ToppCell | 5'-Adult-LargeIntestine-Endothelial-lymphatic_endothelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.80e-04 | 198 | 9 | 2 | 5d42f4fda2081ea3e9f62a00e7eea702e0d0be7d | |
| ToppCell | 5'-Adult-LargeIntestine-Endothelial-lymphatic_endothelial-LEC6_(ADAMTS4+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.80e-04 | 198 | 9 | 2 | 99d6a64f3410dae3019161feef20a8f06081a24b | |
| ToppCell | facs-Tongue-nan-3m|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.80e-04 | 198 | 9 | 2 | f2a4057f038ef7225a5b98a7ab068c30dff4eadd | |
| ToppCell | Brain_organoid-organoid_Velasco_nature-3_mon-Neuronal-CPNs|3_mon / Sample Type, Dataset, Time_group, and Cell type. | 6.80e-04 | 198 | 9 | 2 | 60d8d3bbd754ffde41c50013d822667b185a9751 | |
| ToppCell | 3'-Broncho-tracheal-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.2.4|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.80e-04 | 198 | 9 | 2 | 77517df37dc894c78ef1e2b24dd7ba31f928bdb7 | |
| ToppCell | NS-critical-d_07-13|critical / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 6.80e-04 | 198 | 9 | 2 | a6e11c87b31beffb6af190c64b4ef3ee1d9dab8d | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type. | 6.87e-04 | 199 | 9 | 2 | 77b4aa00f14b86ef5db0490be98787e063979541 | |
| ToppCell | 3'-Adult-LargeIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.87e-04 | 199 | 9 | 2 | 0075bcc7d2a5031e76a24cb176e16ac998d846fd | |
| ToppCell | facs-Trachea-nan-3m-Mesenchymal|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.87e-04 | 199 | 9 | 2 | 67f78c070c56e44fba36542041bf7fa1c291807c | |
| ToppCell | facs-Tongue-nan-3m-Epithelial-nan|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.87e-04 | 199 | 9 | 2 | 8d50e1ee58710d896c0204937331d9f4dcd38de0 | |
| ToppCell | facs-Trachea-nan-3m-Mesenchymal-nan|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.87e-04 | 199 | 9 | 2 | 1ae244b563f85c1ee8d22698f478c842a4d9c7f5 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal|GW26 / Sample Type, Dataset, Time_group, and Cell type. | 6.87e-04 | 199 | 9 | 2 | a255484ba77bd2741a541da278efc8cf4abbe570 | |
| ToppCell | Fibroblasts|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 6.87e-04 | 199 | 9 | 2 | 40de6d4a31cf22efa2864f79e4ec8e2b7bfc9d4a | |
| ToppCell | Tracheal-10x5prime-Stromal-Schwann-Schwann_Myelinating|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.87e-04 | 199 | 9 | 2 | 2b567b6fd8addf059bbf2b72c55a7647aefdc595 | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-3.5_mon-Neuronal-CPNs|3.5_mon / Sample Type, Dataset, Time_group, and Cell type. | 6.93e-04 | 200 | 9 | 2 | 71cbefbef4ae5bbb5f6e419914f4b3b3b5a5f9e3 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuroepithelial|6m / Sample Type, Dataset, Time_group, and Cell type. | 6.93e-04 | 200 | 9 | 2 | 2cc98abf11f5b58707de45a2282f03d47f00f035 | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 6.93e-04 | 200 | 9 | 2 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuroepithelial-Proteoglycan-expressing_cell|6m / Sample Type, Dataset, Time_group, and Cell type. | 6.93e-04 | 200 | 9 | 2 | 0f7431f670f3a175377cefae3479403a881bb8fb | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-3m-Neuronal|3m / Sample Type, Dataset, Time_group, and Cell type. | 6.93e-04 | 200 | 9 | 2 | af99d90070e2933fd2e9512590c6cf3bd6e15539 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal|6m / Sample Type, Dataset, Time_group, and Cell type. | 6.93e-04 | 200 | 9 | 2 | cedbc47b1defb5973cf7ab6baaa2d6f2fd481f88 | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 6.93e-04 | 200 | 9 | 2 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | Bronchial-10x5prime-Endothelial-Endothelia_vascular-VE_pulmonary_arterial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 6.93e-04 | 200 | 9 | 2 | 7547d6339f9380d031cfd2cce21ac9a12491e085 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal-Cortical_neuron|6m / Sample Type, Dataset, Time_group, and Cell type. | 6.93e-04 | 200 | 9 | 2 | 6f7ff0533339fcc9d316f2c77334a79c1409ec4f | |
| Drug | Plant Oils | 2.57e-05 | 496 | 9 | 4 | ctd:D010938 | |
| Drug | Luteolin [491-70-3]; Down 200; 14uM; MCF7; HT_HG-U133A | 4.63e-05 | 190 | 9 | 3 | 3379_DN | |
| Drug | Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A | 4.70e-05 | 191 | 9 | 3 | 5204_DN | |
| Drug | Tetrahydroalstonine [6474-90-4]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 4.85e-05 | 193 | 9 | 3 | 6209_UP | |
| Drug | GW8510; Up 200; 10uM; MCF7; HT_HG-U133A | 4.85e-05 | 193 | 9 | 3 | 7080_UP | |
| Drug | Flufenamic acid [530-78-9]; Down 200; 14.2uM; PC3; HT_HG-U133A | 5.00e-05 | 195 | 9 | 3 | 2104_DN | |
| Drug | Hecogenin [467-55-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 5.00e-05 | 195 | 9 | 3 | 3457_DN | |
| Drug | Nizatidine [76963-41-2]; Down 200; 12uM; HL60; HT_HG-U133A | 5.00e-05 | 195 | 9 | 3 | 3047_DN | |
| Drug | Sulfaguanidine [57-67-0]; Up 200; 18.6uM; MCF7; HT_HG-U133A | 5.08e-05 | 196 | 9 | 3 | 1495_UP | |
| Drug | topiramate; Down 200; 3uM; MCF7; HT_HG-U133A_EA | 5.08e-05 | 196 | 9 | 3 | 915_DN | |
| Drug | Amodiaquin dihydrochloride dihydrate [6398-98-7]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 5.16e-05 | 197 | 9 | 3 | 3186_DN | |
| Drug | Alprostadil [745-65-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 5.16e-05 | 197 | 9 | 3 | 7358_DN | |
| Drug | Bupropion hydrochloride [31677-93-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 5.16e-05 | 197 | 9 | 3 | 3180_DN | |
| Drug | Chicago sky blue 6B [2610-05-1]; Down 200; 4uM; MCF7; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 3266_DN | |
| Drug | Ioxaglic acid [59017-64-0]; Up 200; 3.2uM; HL60; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 2966_UP | |
| Drug | Terbutaline hemisulfate [23031-32-5]; Up 200; 7.2uM; MCF7; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 6240_UP | |
| Drug | Rilmenidine hemifumarate [54187-04-1]; Up 200; 8.4uM; HL60; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 3133_UP | |
| Drug | haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 6963_DN | |
| Drug | Amiloride hydrochloride dihydrate [17440-83-4]; Up 200; 13.2uM; MCF7; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 1470_UP | |
| Drug | Dextromethorphan hydrobromide monohydrate [6700-34-1]; Up 200; 10.8uM; HL60; HT_HG-U133A | 5.39e-05 | 200 | 9 | 3 | 1281_UP | |
| Drug | bromovanin | 1.08e-03 | 127 | 9 | 2 | ctd:C515564 | |
| Drug | Proscillaridin A [466-06-8]; Up 200; 7.6uM; MCF7; HT_HG-U133A | 1.71e-03 | 160 | 9 | 2 | 4404_UP | |
| Drug | Digoxigenin [1672-46-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 1.71e-03 | 160 | 9 | 2 | 5275_UP | |
| Drug | Lanatoside C [17575-22-3]; Up 200; 4uM; PC3; HT_HG-U133A | 1.75e-03 | 162 | 9 | 2 | 3771_UP | |
| Drug | Proscillaridin A [466-06-8]; Up 200; 7.6uM; MCF7; HT_HG-U133A | 1.75e-03 | 162 | 9 | 2 | 7340_UP | |
| Drug | Lanatoside C [17575-22-3]; Up 200; 4uM; MCF7; HT_HG-U133A | 1.80e-03 | 164 | 9 | 2 | 3852_UP | |
| Drug | Lanatoside C [17575-22-3]; Up 200; 4uM; MCF7; HT_HG-U133A | 1.80e-03 | 164 | 9 | 2 | 3963_UP | |
| Drug | Helveticoside [630-64-8]; Up 200; 7.4uM; PC3; HT_HG-U133A | 1.82e-03 | 165 | 9 | 2 | 3770_UP | |
| Drug | Digoxin [20830-75-5]; Up 200; 5.2uM; PC3; HT_HG-U133A | 1.91e-03 | 169 | 9 | 2 | 6724_UP | |
| Drug | Digoxigenin [1672-46-4]; Up 200; 10.2uM; PC3; HT_HG-U133A | 1.93e-03 | 170 | 9 | 2 | 4680_UP | |
| Drug | Strophantine octahydrate [11018-89-6]; Up 200; 5.4uM; MCF7; HT_HG-U133A | 1.95e-03 | 171 | 9 | 2 | 5026_UP | |
| Drug | 17-AAG; Up 200; 1uM; HL60; HT_HG-U133A | 2.02e-03 | 174 | 9 | 2 | 1166_UP | |
| Drug | Withaferin A [5119-48-2]; Down 200; 1uM; PC3; HT_HG-U133A | 2.13e-03 | 179 | 9 | 2 | 4554_DN | |
| Drug | geldanamycin; Up 200; 1uM; MCF7; HT_HG-U133A | 2.23e-03 | 183 | 9 | 2 | 6946_UP | |
| Drug | CPG-oligonucleotide | 2.25e-03 | 184 | 9 | 2 | ctd:C408982 | |
| Drug | Hydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; HL60; HG-U133A | 2.25e-03 | 184 | 9 | 2 | 1772_DN | |
| Drug | Niclosamide [50-65-7]; Down 200; 12.2uM; PC3; HG-U133A | 2.30e-03 | 186 | 9 | 2 | 1916_DN | |
| Drug | Harmine hydrochloride [343-27-1]; Down 200; 16uM; HL60; HG-U133A | 2.33e-03 | 187 | 9 | 2 | 1758_DN | |
| Drug | Nifuroxazide [965-52-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A | 2.35e-03 | 188 | 9 | 2 | 4835_DN | |
| Drug | Rescinnamin [24815-24-5]; Up 200; 6.4uM; MCF7; HT_HG-U133A | 2.35e-03 | 188 | 9 | 2 | 4386_UP | |
| Drug | haloperidol; Up 200; 10uM; MCF7; HT_HG-U133A | 2.37e-03 | 189 | 9 | 2 | 6960_UP | |
| Drug | carbamazepine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA | 2.37e-03 | 189 | 9 | 2 | 835_UP | |
| Drug | Fluvoxamine maleate [61718-82-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.40e-03 | 190 | 9 | 2 | 4114_DN | |
| Drug | Gabazine [105538-73-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A | 2.40e-03 | 190 | 9 | 2 | 3253_DN | |
| Drug | Doxycycline hydrochloride [10592-13-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 2.42e-03 | 191 | 9 | 2 | 7195_UP | |
| Drug | 17-DMAG; Up 200; 0.1uM; MCF7; HT_HG-U133A | 2.42e-03 | 191 | 9 | 2 | 6933_UP | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 3114_UP | |
| Drug | geldanamycin; Down 200; 1uM; MCF7; HG-U133A | 2.45e-03 | 192 | 9 | 2 | 611_DN | |
| Drug | Norethynodrel [68-23-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 1696_UP | |
| Drug | 2-propylpentanoic acid; Up 200; 1000uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 5206_UP | |
| Drug | 3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 3382_DN | |
| Drug | 17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 6978_DN | |
| Drug | Tiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 6013_DN | |
| Drug | Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 1646_DN | |
| Drug | C75; Down 200; 10uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 6423_DN | |
| Drug | Bretylium tosylate [61-75-6]; Down 200; 9.6uM; HL60; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 3057_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 3077_DN | |
| Drug | CP-690334-01 [459212-38-5]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 4380_DN | |
| Drug | radicicol, diheterospora chlamydosporia; Up 200; 0.1uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 6938_UP | |
| Drug | CP-320650-01 [172079-28-6]; Down 200; 1uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 3908_DN | |
| Drug | Danazol [17230-88-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 5315_UP | |
| Drug | Methylhydantoin-5-(L) [40856-73-3]; Down 200; 35uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 3378_DN | |
| Drug | Gallamine triethiodide [65-29-2]; Down 200; 4.4uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 6215_DN | |
| Drug | Azacytidine-5 [320-67-2]; Up 200; 16.4uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 3348_UP | |
| Drug | Tiaprofenic acid [33005-95-7]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 2852_UP | |
| Drug | chlorpromazine hydrochloride; Down 200; 1uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 1642_DN | |
| Drug | Lasalocid sodium salt [25999-20-6]; Down 200; 6.6uM; HL60; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 3021_DN | |
| Drug | Pimethixene maleate [13187-06-9]; Down 200; 9.8uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 7468_DN | |
| Drug | Sulfamonomethoxine [1220-83-3]; Down 200; 14.2uM; HL60; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 2742_DN | |
| Drug | Benzydamine hydrochloride [132-69-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 3169_DN | |
| Drug | Methyl benzethonium chloride [25155-18-4]; Down 200; 8.6uM; PC3; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 4325_DN | |
| Drug | Mefenamic acid [61-68-7]; Down 200; 16.6uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 1699_DN | |
| Drug | Retrorsine [480-54-6]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 2784_DN | |
| Drug | radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 5216_DN | |
| Drug | Thonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 6457_UP | |
| Drug | Memantine Hydrochloride [41100-52-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 7354_DN | |
| Drug | Fusaric acid [536-69-6]; Up 200; 22.4uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 3245_UP | |
| Drug | Erythromycin [114-07-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 5329_UP | |
| Drug | 5211181; Up 200; 12uM; MCF7; HT_HG-U133A_EA | 2.53e-03 | 195 | 9 | 2 | 834_UP | |
| Drug | Acetohexamide [968-81-0]; Up 200; 12.4uM; HL60; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 1870_UP | |
| Drug | Gallamine triethiodide [65-29-2]; Up 200; 4.4uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 6215_UP | |
| Drug | Pindolol [13523-86-9]; Down 200; 16.2uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 6834_DN | |
| Drug | CP-690334-01 [459212-38-5]; Down 200; 1uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 3909_DN | |
| Drug | Pentamidine isethionate [140-64-7]; Down 200; 6.8uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 4396_DN | |
| Drug | Butoconazole nitrate [32872-77-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 5388_DN | |
| Drug | DL-PPMP; Down 200; 2uM; MCF7; HT_HG-U133A_EA | 2.53e-03 | 195 | 9 | 2 | 1121_DN | |
| Disease | MiT family translocation renal cell carcinoma | 1.74e-06 | 7 | 9 | 2 | C4518356 | |
| Disease | biological sex | 2.10e-03 | 230 | 9 | 2 | PATO_0000047 | |
| Disease | amino acid measurement | 1.71e-02 | 678 | 9 | 2 | EFO_0005134 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| DLEERRMRQINEVMR | 316 | P51693 | |
| MNREDRNVLRMKERE | 1 | Q9UHB7 | |
| REEEMRRQQEEMMRR | 351 | Q15233 | |
| RRQQEEMMRRQQEGF | 356 | Q15233 | |
| RREREMQQEMMLRDE | 551 | O14782 | |
| EMRREEEEMQRRRAK | 666 | Q68D10 | |
| FRVPEEERMQQRREM | 1546 | Q5VT25 | |
| EERMQQRREMLRDPE | 1551 | Q5VT25 | |
| RQDLMRRQEELRRME | 536 | P23246 | |
| RQEEERRRREEEMMI | 566 | P23246 | |
| RRRREEEMMIRQREM | 571 | P23246 | |
| RQREMEEQMRRQREE | 581 | P23246 | |
| MTEDIMRDRIEQVRR | 131 | Q7Z5L4 | |
| QMERERIRMRQEELM | 241 | Q9GZV5 |